Answers are grounded in this paper and cite their sources.
Systematic review shows bimekizumab's efficacy for long-term treatment in moderate-to-severe hidradenitis suppurativa, indicating a promising option.
Compared with other approved biologics, bimekizumab showed favourable efficacy across the majority of outcomes assessed at Week 48-52, indicating its potential as a durable long-term therapeutic option for patients with moderate-to-severe HS.
No takes yet. Share an insight, caveat, or question.
Tzellos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: